NL-1

NL-1 is a mitoNEET inhibitor with antileukemic effect. NL-1 inhibits REH and REH/Ara-C cells growth with IC50s of 47.35 μM and 56.26 μM, respectively. NL-1-mediated death in leukemic cells requires the activation of the autophagic pathway[1].

Product Specifications

CAS Number

[188532-26-5]

UNSPSC

12352005

Hazard Statement

H302, H312, H332

Target

Autophagy; Mitochondrial Metabolism

Type

Reference compound

Related Pathways

Autophagy; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/nl-1.html

Purity

99.45

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

O=C(N1)SC(CC2=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C2)C1=O

Molecular Formula

C18H25NO3S

Molecular Weight

335.46

Precautions

H302, H312, H332

References & Citations

[1]Geldenhuys WJ, et al. The MitoNEET Ligand NL-1 Mediates Antileukemic Activity in Drug-Resistant B-Cell Acute Lymphoblastic Leukemia. J Pharmacol Exp Ther. 2019 Jul;370 (1) :25-34.